Association of Extended Dosing Intervals or Delays in Pembrolizumab-based Regimens With Survival Outcomes in Advanced Non–small-cell Lung Cancer

BACKGROUND: Besides modeling/simulation-based analysis, no post-approval studies have evaluated the optimal administration frequency of pembrolizumab in non–small-cell lung cancer (NSCLC). PATIENTS AND METHODS: We performed a multicenter retrospective cohort study to evaluate the association between...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Lung Cancer
Main Authors: Sehgal, Kartik, Bulumulle, Anushi, Brody, Heather, Gill, Ritu R., Macherla, Shravanti, Qilleri, Aleksandra, McDonald, Danielle C., Cherry, Cynthia R., Shea, Meghan, Huberman, Mark S., VanderLaan, Paul A., Weiss, Glen J., Walker, Paul R., Costa, Daniel B., Rangachari, Deepa
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Inc. 2021
Assuntos:
Original Study
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7273162/
https://ncbi.nlm.nih.gov/pubmed/32653295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2020.05.028
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados